|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Com-parison of idarubicin+ara-C,fludarabine+ara-C,andtopotecan+ara-C-based regimens in treatment ofnewly diagnosed acute myeloid leukemia,refractory a-nemia with excess blasts in transformation,or refrac-tory anemia with excess blasts显示文摘 | ESTEY E H THALL P F CORTES J E | 2001 | Blood2001，98，： | 1 |
| 2 | Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts intransformatio, or acute myeloid leukemia ) on outcome of AML-type chemotherapy显示文摘 | Estey E H Thall P Beran M | 1997 | Blood1997，90，8： | 1 |
| 3 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia显示文摘 | ANDERSSON B S THALL P F MADDEN T | 2002 | Biol Blood Marrow Transplantation2002，8，9： | 1 |
| 4 | Some covariance models for longitudinal data with overdispersion显示文摘 | Thall P F Vail SC | 1990 | Biometrics1990，46，4： | 1 |
| 5 | The α-( 1, 3 )fucosyltransferase Fuc-TVⅡ controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis 显示文摘 | Maly P Thall B Petryniak CE | 1996 | Cell1996，86，： | 1 |
| 6 | Mixed Poisson Likelihood Regression Models for Longitudinal Interval Count Data显示文摘 | Thall P F | 1988 | Biometrics1988，44，： | 1 |
| 7 | Platelet-de- rived growth factor receptor inhibition and chemotherapy for cas- tration-resistant prostate cancer with bone metastases显示文摘 | MATHEW P THALL PF BUCANA CD | 2007 | Clin Cancer Res2007，13，19： | 1 |
| 8 | Use of granulocyte colony- stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor 显示文摘 | Estey E Thall P Andreeff M | 1994 | J Clin Oncol1994，12，4： | 1 |
| 9 | Thiotepa,busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia显示文摘 | Przepiorka D Khouri I Thall P | 1999 | Bone Marrow Transplant1999，23，1： | 1 |
| 10 | Caspase-2 and Caspase-3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia显示文摘 | Faderl S Thall P F Kantarjian H M | 1999 | Clin Cancer Res1999，5，12： | 1 |
| 11 | Analysis of CD7 expression in at cute myelogenous leukemia:martingale residual plost combined with optimal cutpoint analysis reveals absence of prognostic signifi- cance显示文摘 | Kornblau S M Thall P Huh Y O | 1995 | Leukemia1995，9，10： | 1 |
| 12 | High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies 显示文摘 | Nieto Y Thall P Valdez B | 2012 | Biol Blood Manw Transplant2012，18，11： | 1 |
| 13 | Effect of Time to Complete Remission on Subsequent Survival and Disease Free Survival Time in AML,RA EB-t,RAEB显示文摘 | Estey E H Shen Y Thall P F | 2000 | Blood2000，95，1： | 1 |
| 14 | Mainte nance therapy with low-dose zazcitidine after alloge- neic hematopoietic stem cell transplantation for recur- rent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study 显示文摘 | DE LIMA M GIRALT S THALL P F | 2010 | Cancer2010，116，： | 1 |
| 15 | High-dose infusional gemcitabine combined with busulfan and melphalan with autologeus stem-cell transplantation in patients with refractory lymphoid malignancies 显示文摘 | Nieto Y Thall P Valdez B | 2012 | Biol Blood Marrow Transplant2012，18，11： | 1 |
| 16 | A bozogamicion with or without interleukin-11 in patients 65 years of age or older with untreated acute myeloid leukemia and high risk myelody splastic syndrome: comparison with indarubicin plus continous infusion, high dosecytosi near abionside显示文摘 | Estey E Thall P Tuzum G | 2002 | Blood2002，99，： | 1 |
| 17 | Analysis of CD7 expression in acute myelogenous leuke mia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance 显示文摘 | KORNBLAU S M THALL P HUH Y O | 1995 | Leukemia1995，9，： | 1 |
| 18 | Comparison of idarubicin +ara-C-,fludarabine +ara-C-,and topotecan +ara-C-,based regimens in treat ment of newly diagnosed acute myeloid leukemia,refractory anemia with excess blasts in transformation,or refractory anemia with excess blasts显示文摘 | Estey E H Thall P F Cortes J E | 2001 | Blood2001，98，： | 1 |
| 19 | Effect of time to complete remission on subsequent survival and disease free survival time in AML, RAEB - T, RAEB显示文摘 | ESTEY E H SHEN Y THALL P F | 2000 | Blood2000，95，1： | 1 |
| 20 | Comparison of idarubicin + ara - C - , fludarabine + ara - C - , and topotecan + ara- C- based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transfor- mation, or refractory anemia with excess blasts显示文摘 | ESTEY E H THALL P F CORTES J E | 2001 | Blood2001，98，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员